CAPSTONE HEALTH SERVICES FOUNDATION PC

850 5TH AVE E

Articles

AAO Spokesperson: FDA Approval of Byooviz, First Biosimilar to Lucentis, Is “Significant"

October 07, 2021

Exactly how Byooviz will be priced is unclear, noted George W. Williams, M.D., a retina specialist and past president of the American Academy of Ophthalmology. The exact cost savings will help determine whether the biosimilar gains acceptance.

Rituximab Biosimilars Produce Big Cost Savings, are Effective

September 07, 2021

A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43 percent reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.